20040010.TNBC
— · F
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- F
- subtype
- F
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ADIPOGENESIS+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- COAGULATION+0.450
- CHOLESTEROL_HOMEOSTASIS+0.440
- XENOBIOTIC_METABOLISM+0.420
- FATTY_ACID_METABOLISM+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
- ANDROGEN_RESPONSE+0.360
- ANGIOGENESIS+0.360
- BILE_ACID_METABOLISM+0.360
Top 10 suppressed
- MYC_TARGETS_V1-0.370
- WNT_BETA_CATENIN_SIGNALING-0.330
- MYC_TARGETS_V2-0.310
- E2F_TARGETS-0.290
- G2M_CHECKPOINT-0.260
- MITOTIC_SPINDLE-0.240
- DNA_REPAIR-0.060
- KRAS_SIGNALING_DN-0.040
- SPERMATOGENESIS-0.030
- HEDGEHOG_SIGNALING-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518315 | — | F | 0.879 |
| 2 | 20030075.TNBC | — | C | 0.872 |
| 3 | SRR15030876 | — | — | 0.872 |
| 4 | TCGA-CN-4726-01A-01R-1436-07 | — | — | 0.869 |
| 5 | SNU878_LIVER | HCC | — | 0.853 |
| 6 | SRR15030885 | — | — | 0.852 |
| 7 | SRR8518286 | — | F | 0.850 |
| 8 | SRR15030843 | — | — | 0.848 |
| 9 | SRR8518325 | — | F | 0.836 |
| 10 | 4c075dfa-f213-4e97-9c4e-6aac7b8345c7 | — | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ADIPOGENESIS | 0.480 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| COAGULATION | 0.450 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.440 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.420 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PEROXISOME | 0.320 | Idelalisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.270 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |